

a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein:

p represents an integer being 0, 1, 2, 3 or 4;

X represents O, S, NR⁵ or a direct bond or-X-R² taken together may represent cyano; Y represents O, S, NR⁵, or S(O)₂;

each R¹ independently represents C(=0)·Z-R¹⁴, C₁₋₆alkyl, halo, polyhaloC₁₋₆alkyl, hydroxy, mercapto, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkylcarbonyloxy, aryl, cyano, nitro, Het³, R⁶, NR⁷R⁸ or C₁₋₄alkyl substituted with C(=0)-Z·R¹⁴, Het³, R⁶ or NR⁷R⁸;

represents Het¹, C_{3-7} cycloalkyl optionally substituted with C(=0)-Z- R^{14} , C_{1-6} alkyl or C_{1-6} alkyl substituted with one or two substituents selected from C(=0)-Z- R^{14} , hydroxy, cyano, amino, mono- or di(C_{1-4} alkyl)amino, C_{1-6} alkyloxy optionally substituted with C(=0)-Z- R^{14} , C_{1-6} alkylsulfonyloxy, C_{3-7} cycloalkyl optionally substituted with C(=0)-Z- R^{14} , aryl, aryloxy, arylthio, Het¹, Het¹oxy and Het¹thio; and if X is O, S or NR^5 , then R^2 may also represent aminothiocarbonyl, C_{1-4} alkylcarbonyl optionally substituted with C(=0)-Z- R^{14} , C_{1-4} alkylthiocarbonyl optionally substituted with C(=0)-Z- R^{14} , arylcarbonyl, arylthiocarbonyl, Het¹carbonyl or Het¹thiocarbonyl;

R³ represents hydrogen, C₁₋₆alkyl or C₃₋₇cycloalkyl;

R⁴ represents hydrogen, C₁₋₆alkyl or C₃₋₇cycloalkyl; or


 $-R^{3}$ and $-R^{4}$ taken-together form a $-C_{2-6}$ alkanediyl;

R⁵ represents hydrogen or C₁₋₄alkyl;

each R⁶ independently represents C₁₋₆alkylsulfonyl, aminosulfonyl, piperidinylsulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, mono- or di(benzyl)aminosulfonyl, polyhaloC₁₋₆alkylsulfonyl, C₁₋₆alkylsulfinyl, phenylC₁₋₄alkylsulfonyl, piperazinylsulfonyl, aminopiperidinylsulfonyl, piperidinylaminosulfonyl, N-C₁₋₄alkyl-N-piperidinylaminosulfonyl or mono-or di(C₁₋₄alkyl)aminoC₁₋₄alkylsulfonyl;

each R⁷ and each R⁸ are independently selected from hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, dihydroxyC₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkylcarbonyl, arylcarbonyl, Het³carbonyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het³aminocarbonyl, Het³aminothiocarbonyl, C₃₋₇cycloalkyl, pyridinylC₁₋₄alkyl, C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, -C(=O)-Z-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, Het³, Het⁴ and R⁶; or R⁷ and R⁸ taken together with the nitrogen atom to which they are attached form a radical of formula

R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, dihydroxyC₁₋₄alkyl, phenyl, phenylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkylcarbonyl, phenylcarbonyl, Het³carbonyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het³aminocarbonyl, Het³aminothiocarbonyl, C₃₋₇cycloalkyl, pyridinylC₁₋₄alkyl, C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, -C(=O)-Z-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, Het³, Het⁴ and R⁶; or R⁹ and R¹⁰ taken together with the nitrogen atom to which they are attached form a radical of formula



each R¹¹ independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C₁₋₄alkyloxy optionally substituted with C(=0)-Z-R¹⁴, formyl, trihaloC₁₋₄alkylsulfonyloxy, R⁶, NR⁷R⁸, C(=O)NR¹⁵R¹⁶, -C(=O)-Z-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, aryl, aryloxy, arylcarbonyl, C₃₋₇cycloalkyl optionally substituted with

Serial No. 09/____

C(=0)-Z- R^{14} , C_{3-7} cycloalkyloxy optionally substituted with C(=0)-Z- R^{14} , phthalimide-2-yl, Het³, Het⁴ and C(=0)Het³;

 R^{12} and R^{13} are each independently selected from hydrogen, C_{1-4} alkyl, hydroxy C_{1-4} alkyl, dihydroxy C_{1-4} alkyl, phenyl, phenyl C_{1-4} alkyl, C_{1-4} alkyloxy C_{1-4} alkyl, C_{1-4} alkyl, C_{1-4} alkyl, C_{1-4} alkyl, carbonyl, phenylcarbonyl, mono- or di(C_{1-4} alkyl)amino C_{1-4} alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C_{3-7} cycloalkyl, pyridinyl C_{1-4} alkyl, C_{1-4} alkanediyl-C(=O)-Z- R^{14} , -C(=O)-Z- R^{14} , -Y- C_{1-4} alkanediyl-C(=O)-Z- R^{14} and R^{6} ; or R^{12} and R^{13} taken together with the nitrogen atom to which they are attached form a radical of formula

each R^{14} independently represents hydrogen, $C_{1\text{-}20}$ acyl (having a straight or branched, saturated or unsaturated hydrocarbon chain having 1 to 20 carbon atoms), $C_{1\text{-}20}$ alkyl, $C_{3\text{-}20}$ alkenyl optionally substituted with phenyl, $C_{3\text{-}20}$ alkynyl, $C_{3\text{-}7}$ cycloalkyl, polyhalo $C_{1\text{-}20}$ alkyl, Het⁵, phenyl or $C_{1\text{-}20}$ alkyl substituted with one or more substituents selected from hydroxy, $NR^{17}R^{18}$, phenyl, mono- or di- $(C_{1\text{-}4}$ alkyl)amino, cyano, Het⁵, $C_{1\text{-}4}$ alkyloxycarbonyl and $C_{3\text{-}7}$ cycloalkyl, or R^{14} represents a radical of formula

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_2 & O
\end{pmatrix}$$

$$\begin{pmatrix}
CH_2 & O \\
CH_$$

$$(R_i)_s \qquad (R_i)_s \qquad (R_i$$

wherein m is 1 to 4, n is 0 to 5, q is 0 to 2, r is 0 to 2 and s is 0 to 4;

 R^a , R^b , R^c , R^d , R^e and R^f are each independently hydrogen, C_{1-6} alkyl, phenyl or C_{3-7} cycloalkyl; or

Re and Rf taken together may form -CH2-CH2-, -CH2-CH2-CH2- or -CH2-CH2-CH2-CH2-;

 R_g , R_h and R_k are each independently hydrogen or C_{1-4} alkyl;

R_i is C₁₋₄alkyl;

 $R_{j}\,is\,-O-R_{b,}\,C_{1\text{--}6}alkyl,\,phenyl\,or\,\,C_{3\text{--}7}cycloalkyl\,optionally\,substituted\,\,with\,\,C_{1\text{--}4}\,\,alkyloxy;$

where R_m is hydrogen or $C_{1\text{--}4}$ alkyloxy and R_n is hydrogen, $C_{1\text{--}4}$ alkyl,

C₃₋₇cycloalkyl, phenyl or phenylC₁₋₄alkyl

each Z independently represents O, S, NH, -CH₂-O- or -CH₂-S- whereby -CH₂- is attached to the carbonyl group; or

-Z-R¹⁴ taken together form a radical of formula

$$CH_2$$
 CN
 CH_2
 CH

 R^{15} and R^{16} are each independently selected from hydrogen, C_{1-4} alkyl, hydroxy C_{1-4} alkyl, dihydroxy C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, C_{1-4} alkyloxy C_{1-4} alkyl, -C(=O)-Z- R^{14} , arylcarbonyl, mono- or di(C_{1-4} alkyl)amino C_{1-4} alkyl, arylaminocarbonyl, arylaminothiocarbonyl, aminocarbonylmethylene, mono- or di(C_{1-4} alkyl) aminocarbonylmethylene, Het³aminocarbonyl, Het³aminothiocarbonyl, pyridinyl C_{1-4} alkyl, Het³ or R^{6} ; or R^{15} and R^{16} taken together with the nitrogen atom to which they are attached form a radical of formula

R¹⁷ and R¹⁸ are each independently selected from hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, dihydroxyC₁₋₄alkyl, phenyl, phenylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkylcarbonyl, phenylcarbonyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C₃₋₇cycloalkyl, pyridinylC₁₋₄alkyl, C₁₋₄alkanediyl-C(=O)-Z-C₁₋₆alkyl, -C(=O)-Z-C₁₋₆alkyl, -Y-C₁₋₄alkanediyl-C(=O)-Z-C₁₋₆alkyl and R⁶; aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, cyano, halo, hydroxy, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₁₋₄alkyloxy, formyl, polyhaloC₁₋₄alkyl, NR⁹R¹⁰, C(=O)NR⁹R¹⁰, C(=O)-Z-R¹⁴, R⁶, -O-R⁶, phenyl, Het³, C(=O)Het³ and C₁₋₄alkyl substituted with one or more substituents each independently selected from halo, hydroxy, C₁₋₄alkyloxy, C(=O)-Z-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, Het³ or NR⁹R¹⁰;

Het¹ represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl,

pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with one or two substituents independently selected from Het² and R¹¹;

Het² represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolyl, pyrazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het⁴, R¹¹ and C₁₋₄alkyl optionally substituted with one or two substituents independently selected from Het⁴ and R¹¹;

Het³ represents a monocyclic heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy, C₁₋₄alkylcarbonyl, piperidinyl, NR¹²R¹³, C(=O)-Z-R¹⁴, R⁶ and C₁₋₄alkyl substituted with one or two substituents independently selected from hydroxy, C₁₋₄alkyloxy, phenyl, C(=O)-Z-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-Z-R¹⁴, R⁶ and NR¹²R¹³;

Het⁴ represents a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl;

Het⁵ represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy, C₁₋₄alkylcarbonyl, piperidinyl, NR¹⁷R¹⁸, C(=O)-Z-C₁₋₆alkyl, R⁶, sulfonamido and C₁₋₄alkyl substituted with one or two substituents independently selected from hydroxy, C₁₋₄alkyloxy, phenyl, C(=O)-Z-C₁₋₆alkyl, $-Y-C_{1-4}$ alkanediyl-C(=O)-Z-C₁₋₆alkyl, R^6 and $NR^{17}R^{18}$; provided however that

- R² is other than C₁₋₆ alkyloxycarbonylC₁₋₆alkyl or aminocarbonyl; and
- R⁷, R⁸, R⁹ and R¹⁰ are other than aminocarbonyl, C₁₋₄alkylcarbonyloxy-C₁₋₄alkylcarbonyl, hydroxy C₁₋₄alkylcarbonyl, C₁₋₄alkyloxycarbonylcarbonyl, C(=O)-O-R¹⁹, C₁₋₄alkanediylC(=O)-O-R¹⁹ or -Y-C₁₋₄alkanediylC(=O)-O-R¹⁹; and
- R^{12} and R^{13} are other than C_{1-4} alkylcarbonyloxy- C_{1-4} alkylcarbonyl, hydroxy C_{1-4} alkylcarbonyl or C_{1-4} alkylcarbonylcarbonyl; and
- R^{11} is other than C(=O)-O- R^{19} , Y- C_{1-4} alkanediyl C(=O)- OR^{19} , $C(=O)NH_2$, $C(=O)NHC_1$.

 4alkyl or $C(=O)NHC_{3-7}$ cycloalkyl; and
- R¹⁵ and R¹⁶ are other than aminocarbonyl, C₁₋₄alkylcarbonyloxy-C₁₋₄alkylcarbonyl, hydroxy C₁₋₄alkylcarbonyl or C₁₋₄alkyloxycarbonylcarbonyl; and
- aryl is other than phenyl substituted with C(=O)-O-R¹⁹, C(=O)NH₂,
 C(=O)NHC₁₋₄alkyl, C(=O)NHC₃₋₇cycloalkyl and/or with C₁₋₄alkyl substituted with C(=O)-O-R¹⁹ or Y-C₁₋₄alkanediyl C(=O)-O-R¹⁴; and
- Het³ is other than a monocyclic heterocycle substituted with C(=O)·O-R¹⁹ and/or with C₁.

 4alkyl substituted with C(=O)-O-R¹⁹ and/or Y-C₁₋₄alkanediyl (=O)-O-R¹⁹; and

Serial N	lo. 09/	1	

- in each of the above proviso's R¹⁹ is defined as hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, aminocarbonylmethylene or mono- or di(C₁₋₄alkyl)aminocarbonylmethylene; and
- the said compound of formula (I) contains at least one $-C(=O)-Z-R^{14}$ moiety.
- 4. (Amended) A compound according to claim 1 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
- 5. (Amended) A compound according to claim 1 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
- 6. (Amended) A compound according to claim 1 wherein R³ and R⁴ are both methyl and X-R² is Het¹.
- 7. (Amended) A compound according to claim1 wherein p is 1 or 2 and each R¹ is chloro.
- 8. (Amended) A compound according to claim 1 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
- 11. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

Please cancel claims 12 and 13.

Serial No. 0	9/
--------------	----

- 14. (Amended) A method for treating eosinophil-dependent inflammatory diseases comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
- 17. (Amended) A process of imaging an organ, comprising, administering a sufficient amount of a radiolabelled compound of formula (I) as claimed in claim 1 in an appropriate composition, and detecting the emissions from the radioactive compound.

Please cancel claims 19 and 20.